South Korea · Delayed Price · Currency is KRW OLIPASS Company Description
OLIPASS Corporation, a biotech company, focuses on developing therapeutic products in South Korea.
The company develops its products using its novel PNA based technologies. Its products pipeline includes SCN9A, a product candidate that is in Phase II clinical trials for the treatment of pain.
The company also develops PCSK9 for the treatment of hyper cholesterolemia; VEGF for the treatment of AMD/DR; HIF-1a for chemo/radio-sensitizer treatment; Dystrophin for the treatment of duchenne muscular disease; and PTP1B for the treatment of type II diabetes.
It is also involved in the development of CTLA4 immuno-oncology, PD1 immuno-oncology, and NOX4 fibrosis.
In addition, the company engages in the collaborative research and development with OliPass Cosmeceuticals for life style management solutions, as well as Target X1 and Target X2.
OLIPASS Corporation was founded in 2006 and is headquartered in Yongin-si, South Korea.
| Country | South Korea |
| Founded | 2006 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 78 |
| CEO | Shin Chung |
Contact Details
Address: Ace Dongbaek Tower Yongin-si, 17015 South Korea | |
| Phone | 82 2 6488 2232 |
| Website | olipass.com |
Stock Details
| Ticker Symbol | 244460 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Shin Chung | Chief Executive Officer |
| Jae-Hyeon Kim | Chief Financial Officer |